Only 1 week to go until PBAC submissions close (24/9/25)
This is YOUR chance to tell the people who decide if Androfeme gets on to the PBS, why this matters to YOU!
Why This Matters
Currently the estimated 1 million women suffering from Hypoactive Sexual Desire Disorder (HSDD) - ie distressing low libido- face significant barriers to treatment:
COST: ANDROFEME 1 remains unaffordable for many women
ONLY 1 OPTION: No PBS-subsidised alternatives exist for female HSDD
INEQUITY: NINE male testosterone products are PBS-subsidised, NONE for women
Our Goal: Unrestricted or Restricted PBS Listing
We're advocating for ANDROFEME 1 to be listed as either an "Unrestricted" or "Restricted" medicine (not "Authority Required") to ensure:
GPs can prescribe as needed, similar to other female hormones like Estrogel and Prometrium.
Minimal barriers to access for women already facing stigma around sexual health.
Recognition that testosterone is a female hormone deserving equal treatment to estrogen and progesterone.